Cardiff Oncology (CRDF)

1Q26 Announced With Onvansertib Progress Toward Phase 3


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
May 22, 2026
Report ID: 31220
Already Registered?
Click the Get Report button to login and view the full report, with price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Register Now to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Cardiff Oncology Inc.
Cardiff Oncology Inc.
Healthcare
Biotechnology
Ticker
CRDF
Current Price
$1.74 -2.79%
Market Cap
$119.0M
Price Target
Refer to Report
Volume
722.1K
52wk Range
$1.48 - $4.555
© 2018-2026 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.